[1].Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial. Presented at the American Society of Clinical Oncology Annual Meeting; June 2, 2023;...
[1].Slamon D, Stroyakovskiy D, Yardley D, et al. Ribociclib and endocrine therapy as adjuvant treatment in patients with HR+/HER2− early breast cancer: primary results from the Phase III NATALEE trial. Presented at the America...
1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 4.2024, July 3, 2024 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 5.2023, December...
参考文献: 1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 4.2024, July 3, 2024 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 5.2023, December 5, 2023 3. Matteo Lazzeroni, et al. JCO 41, 3116-3121...
b.出自“Hewitt M, Greenfield S, Stovall E. From Cancer Patient to Cancer Survivor: Lost in Transition. Committee on Cancer Survivorship: Improving Care and Quality of Life, Institute of Medicine and National Research Council 2006”。可登陆以下网站获取信息:...
et al. Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial. Presented at San Antonio Breast Cancer Symposium (SABCS); December 8, 2023; San...
1. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 4.2024, July 3, 2024 2. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), Breast Cancer, Version 5.2023, December 5, 2023 3. Matteo Lazzeroni, et al. JCO 41, 3116-3121(2023). ...